Clinical trials - page 8

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

Therapeutic Nipple Areola Skin-sparing Mastectomy.

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.

Phase 3 Randomized Clinical Study of MK-4280A (coformulated;favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus PhysicianÀs Choice;Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma;(KEYFORM-008).

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)